(Sharecast News) - Medical diagnostics company Omega said on Wednesday that the UK Rapid Test Consortium has made "significant progress" in developing a Covid-19 lateral flow antibody test that can be used by people in their homes.
As the lead party of the UK-RTC, Omega said its partner Abingdon Health had been developing a Covid-19 rapid test and made solid progress in just "a short period of time".
Omega stated its role as a member of the UK-RTC was unchanged and will provide volume manufacturing capacity of the test once design freeze has been attained by Abingdon.
Chief executive Colin King said: "I am really impressed with the progress Abingdon have made to date with the development in such a short period of time.
"Everyone is working extremely hard to deliver a high-quality product as soon as possible to help play a part in returning life back to more normal levels in the UK."
As of 1105 BST, Omega shares were down 1.76% at 69.75p.
7 Sep 2020 14:50
IN BRIEF: Omega Diagnostics Completes AbC-19 Self-Test Usability Study
IN BRIEF: Omega Diagnostics Completes AbC-19 Self-Test Usability Study
Read more